Colossal Biosciences IPO
Colossal Biosciences is a biotechnology company focused on de-extinction and genetic engineering, notably working on projects to bring back extinct species like woolly mammoths. The company combines cutting-edge genetic technology with conservation efforts, attracting significant venture funding. Investors are interested in Colossal's potential applications in conservation, agriculture, and genetic medicine.
Key Facts
| Industry | Biotechnology |
| Founded | 2021 |
| Headquarters | Dallas, TX |
| Employees | ~100 |
| Website | colossal.com |
| Funding | Series B at $5.5B valuation. Total raised: ~$225M |
About Colossal Biosciences
Colossal Biosciences is a de-extinction and species preservation company that uses advanced genetic engineering and reproductive technologies to restore extinct species and protect endangered ones. The company's flagship project involves using CRISPR gene editing to create a mammoth-elephant hybrid by inserting mammoth DNA sequences into Asian elephant genomes. Beyond the woolly mammoth, Colossal is working on projects to restore the Tasmanian tiger and the dodo bird.
The company combines cutting-edge biotechnology with conservation goals, arguing that de-extinction efforts can help restore damaged ecosystems and combat climate change. For example, their mammoth project aims to create animals that could help restore Arctic grasslands and reduce permafrost melting. Colossal has assembled a team of leading geneticists and has developed proprietary technologies for multiplex gene editing, artificial wombs, and advanced reproductive techniques that have applications beyond de-extinction in agriculture and medicine.
IPO Status
Colossal Biosciences has raised substantial venture capital funding, with reported valuations reaching over $1 billion, making it a unicorn in the biotech space. However, the company has not announced any plans for an IPO and remains focused on its research and development efforts. Given the early-stage nature of Colossal's technology and the long development timelines typical in biotechnology, an IPO is likely years away. The company would need to demonstrate significant progress in its de-extinction projects and identify clear commercial applications before becoming a viable public company candidate. Biotech IPOs typically require substantial clinical or commercial milestones that Colossal has not yet reached.
Competitors
Frequently Asked Questions
Does Colossal Biosciences have a stock?
No, Colossal Biosciences has not had an IPO yet. The company remains private while developing its de-extinction and genetic engineering technologies.
When is the Colossal Biosciences IPO date?
Colossal Biosciences has not announced an IPO timeline. Given the early-stage nature of their biotechnology research, an IPO is likely several years away.
How can I buy Colossal Biosciences stock?
You cannot buy Colossal Biosciences stock as it is currently a private company. Shares would only become available if the company goes public in the future.
Stay Updated on the Colossal Biosciences IPO
Get real-time alerts when Colossal Biosciences files for an IPO, prices shares, or begins trading.
Get IPO Alerts